Roquette, a global supplier of plant-based pharmaceutical ingredients, announced its commitment to provide new product offerings to address the growing demand for excipients and raw materials for the biopharmaceutical market.
New product offerings are low endotoxin, multi-compendial grade materials for cell culture and biologic drug formulations.
“As a long-time leader in excipients and active ingredients for the pharmaceutical market, Roquette is proud to be part of this major therapeutic progress and is excited to introduce several new products in the U.S., Europe and Asia,” said Paul Smaltz, VP of Global Business Unit Pharma.
“We have three new brands coming to the market under the names Lycadex BioPharma dextrose, Pearlitol BioPharma mannitol, and Neosorb BioPharma sorbitol with a plan to continue adding to the portfolio,” said Kelsey Achenbach, Pharma Marketing Director. “Customers now have an alternative option with a partner who is an established manufacturer and has sole custody of the supply chain when it comes to materials for biopharmaceuticals.”
According to the company, the investment reaffirms tits strategic initiatives to develop specialties for pharma, food, nutrition and health markets to accelerate global growth. The BioPharma market launch addresses the growing customer demand for biologic drugs worldwide. These protein-based drugs can be game-changing by having the ability to put rheumatoid arthritis into remission and transform many cancers into treatable conditions.
A family-owned group serving customers globally, Roquette is involved in specialty food ingredients and pharmaceutical excipients. Founded more than 80 years ago, Roquette operates in over 100 countries, has a sales of around €3.3 billion ($3.5 billion) and currently employs more than 8,000 people worldwide.
€1 = $1.06 on March 14, 2017
(Source: PR Newswire UK)